Skip to main content
OpenTrials
Completed

NCT Number: NCT00255970

Regenafil Versus Demineralized Freeze Dried Bone Allograft (DFDBA) for Periodontal Defects

The purpose of this research study was to determine whether treatment with the bone grafting material Regenafil was as effective as the standard treatment using demineralized freeze dried bone allograft (DFDBA). Regenafil is demineralized freeze dried bone in a special gel form.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Indiana University School of Dentistry, Indianapolis, Indiana, United States

Loading trial locations.

About this study

To compare the regenerative effects of a demineralized freeze dried bone allograft (DFDBA) particulate in a biologic thermoplastic carrier (Regenafil) to the standard of care. To compare the regenerative effects of a demineralized freeze dried bone allograft (DFDBA) particulate in the treatment of intraosseous vertical defects following six months of healing. This was accomplished by evaluating clinical parameters including probing depth, attachment level and bleeding upon probing, using attachment level as the primary outcome variable.

Treatment of the vertical osseous defect is a challenging problem in periodontics. There are many treatment options including:

  • open flap debridement;
  • osseous graft alone;
  • membrane alone;
  • or membrane plus an osseous graft.

Choice of treatment may depend on the defect depth and configuration. A shallow, narrow 3 wall defect may respond well to open flap debridement while a deep 2 wall defect may need regenerative therapy such as an osseous graft, a membrane or combined membrane and graft treatment. Studies of vertical defect therapy with defects about 4 mm or greater show that similar percent defect fill results are obtained with regenerative therapies. Open flap debridement produces substantially less percent defect fill.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Provide written informed consent prior to their participation.
  • Be an adult age 18 and older.
  • Have at least a 4 mm open vertical osseous defect depth on one tooth, visible on a radiograph and with a probing depth ≥ 5 mm.
  • Have osseous defects that are either wide 3-wall, or combination defects.

Exclusion criteria

  • Have debilitating systemic diseases, or diseases that affect the periodontium.
  • Have a known allergy to any of the materials that will be used in the study:
  • non-steroidal anti-inflammatory drugs (NSAIDs)
  • chlorhexidine digluconate
  • doxycycline
  • gelatin
  • Need prophylactic antibiotics.
  • Have a vertical osseous defect that is related to a furcation area.
  • Smoke more than 1 pack per day.
  • Have endodontically treated teeth or endodontic lesions at study sites.
  • Have 1-wall defects.
  • Have poor oral hygiene.
  • Have anterior fillings (Note: if a subject presents with anterior fillings, it will be at the discretion of the principal investigator as to whether they should be accepted into the study.)
  • Be pregnant as evidenced by a positive urine pregnancy test taken at both the screening and baseline visits.

Treatment and study plan

DFDBA

Other

Demineralized Freeze Dried Allograft bone

Other names: Demineralized Bone Matrix

Regenafil

Device

Demineralized Freeze Dried Bone in a porcine gel carrier

Other names: Demineralized Freeze Dried Bone Allograft

Primary outcomes

  1. Change in Probing Depth

    Time frame: baseline and then at 6 months

    This is the distance, measured in millimeters (mm) from the gingival margin to the maximal penetration of the probe tip. The measures were made at baseline and then at 6 months after treatment.

  2. Clinical Attachment Level

    Time frame: 6 months

    The amount of space between attached periodontal tissues and a fixed point, usually the cementoenamel junction. A measurement used to assess the stability of attachment as part of a periodontal maintenance program.

  3. Recession

    Time frame: 6 months

    CEJ to gingival margin (GM). GM coronal to the CEJ were scored as a negative number.

Secondary outcomes

  1. Gingival Index

    Time frame: 6 months

    Scores:

    0 Normal gingiva

    • Mild inflammation
    • Moderate inflammation
    • Severe inflammation Gingival units (buccal, lingual, mesiobuccal, distobuccal, mesiolingual, and distolingual) of each tooth were scored 0-3. Scores from the 6 areas of the tooth were added and divided by 6 to give the gingival index for the entire tooth.
  2. Plaque Index

    Time frame: 6 months

    0- No plaque

    • A film of plaque adhering to gingival margin & adjacent area of tooth
    • Moderate accumulation of soft deposits, visible with the naked eye
    • Abundance of soft matter Each gingival region of the individual tooth will be scored 0-3 The scores from the 6 areas of the tooth are averaged to give the plaque index for the tooth.
  3. Bleeding on Probing

    Time frame: 6 months

    The variable measured the presence of bleeding when the osseus defect was probed. The presence and character of gingival bleeding will be determined by gently probing to the base of the pockets.

    0 - No bleeding.

    1 - Bleeding when probing.

  4. Mobility Index

    Time frame: 6 months

    Tooth mobility was recorded using Miller's Index:

    • - up to 1 mm of movement in a horizontal direction
    • - greater than 1 mm of movement in a horizontal direction
    • - excessive horizontal movement and vertical movement. Manual evaluation of mobility was carried out clinically using the handles of two instruments to move the teeth buccally and lingually and note their movement.

Sponsors and collaborators

Lead sponsor

RTI Surgical

Industry

Registry information

Official study title

Regenerative Therapy for Vertical Defects Comparing Demineralized Freeze Dried Bone Allograft (DFDBA) and Regenafil

Important dates

Study start
2006
Primary completion
2007
Study completion
2007
First posted
Nov 21, 2005
Registry last updated
Aug 10, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.